-
Mol Aspects Med: A New Immune Checkpoint for Cancer Treatment: the Siglec Receptor
Time of Update: 2022-10-19
Recent research suggests that the interaction between sialic acid, which contains sialic acid glycans in the tumor microenvironment, and sialic acid-binding immunoglobulin-like lectin (Siglec) receptors on tumor-infiltrating immune cells may represent a new immune checkpoint and a potential new target for cancer immunotherapy.
-
【One case per day】Chinese Journal of Radiology: A case of invasive osteoblastoma of the shoulder blade complicated with aneurysm-like bone cyst
Time of Update: 2022-10-19
X-ray shows round, uneven high-density opacities (arrows) of the left shoulder blade, surrounded by linear density reduction on the inner side of its upper edge Fig. 2 The CT axis shows the osteogeni
-
Nat Rev Cancer: The future direction of NK cell therapy
Time of Update: 2022-10-19
In any case, CAR-NK cell therapy is a promising clinical research field with good safety and preliminary efficacy for some cancer patients.
In any case, CAR-NK cell therapy is a promising clinical research field with good safety and preliminary efficacy for some cancer patients.
-
Lancet Oncol: Bemarituzumab combined with mFOLFOX6 is promising for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma
Time of Update: 2022-10-19
This is a randomized, double-blind, placebo-controlled phase 2 trial (FIGHT) that recruited patients aged 18 years and older with HER2-positive, FGFR2b-selected gastric or gastric-oesophageal junction adenocarcinoma from 17 countries and excluded patients who had previously received selective inhibitors of the FGF-FGFR pathway.
-
Lancet Respirat Med: Lurbinectedin in combination with doxorubicin for the treatment of recurrent small cell lung cancer
Time of Update: 2022-10-19
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
-
JCO: Professor Wang Jie's team found that Torpalimab combined with chemotherapy works well in the treatment of non-small cell lung cancer
Time of Update: 2022-10-19
The study investigated the efficacy and safety of Torpalimab (tolipalimab) combination chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC).
The study investigated the efficacy and safety of Torpalimab (tolipalimab) combination chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC).
-
Radiology: The value of preoperative MRI for bilateral synchronous breast cancer screening
Time of Update: 2022-10-19
The patient received radiation therapy followed by 5 years of endocrine therapy, and after 11 years of treatment there was no evidence of local or distant recurrenceThe results of this study suggest that a single breast MRI screening of patients with newly diagnosed breast cancer can improve the detection rate of early-stage synchronous breast cancer and further improve the overall survival of patients.
-
J Clin Oncol: Neoadjuvant therapy improves anus preservation in patients with early-stage rectal cancer
Time of Update: 2022-10-16
The purpose of this study was to determine the prognosis and organ preservation rates of patients with early-stage rectal cancer treated with neoadjuvant chemotherapy and transanal excision surgery (TES) .
-
Euro Radio: An MR radiomics model for predicting disease-free and overall survival in patients with esophageal cancer
Time of Update: 2022-10-16
Development and validation of MRI-based radiomics signatures models for prediction of disease-free survival and overall survival in patients with esophageal squamous cell carcinoma.
Development and validation of MRI-based radiomics signatures models for prediction of disease-free survival and overall survival in patients with esophageal squamous cell carcinoma.
-
Scientists from West China Hospital of Sichuan University have discovered a new target for tumor metabolic therapy!
Time of Update: 2022-10-16
translocated (Fig. 2), and DDX39B promoted tumor progression by enhancing aerobic glycolysis by enhancing nuclear PKM2 function in CRC cells .
translocated (Fig. 2), and DDX39B promoted tumor progression by enhancing aerobic glycolysis by enhancing nuclear PKM2 function in CRC cells .
-
European Radiology: The detection value of CT in single-shot microwave ablation of liver tumors
Time of Update: 2022-10-16
Recently, a study published in European Radiology evaluated the value of minimal ablation margin control in MWA monitored by intraoperative CECT for successful ablation of liver tumors, providing the possibility to improve the treatment success rate and prognosis of such patients .
-
Shi Huaiyin: Application of AI in Pathological Diagnosis of Digestive Tract
Time of Update: 2022-10-16
Application of AI in Pathology1) Accurate acquisition of diseased tissue;2) Pathological diagnosis;3) Histological grading and quantitative scoring;4) Evaluation of tumor biomarkers;5) Predict the mol
-
Can this simple and easy-to-obtain indicator predict the postoperative OS of "cancer king" patients?
Time of Update: 2022-10-16
Geriatric nutritional risk index as a potential prognostic marker for patients with resectable pancreatic cancer: a single-center, retrospective cohort study.
Geriatric nutritional risk index as a potential prognostic marker for patients with resectable pancreatic cancer: a single-center, retrospective cohort study.
-
Nature sub-journal: Gene 'Achilles heel' found in ovarian and uterine cancers
Time of Update: 2022-10-16
Disrupting phosphate transport in cancer cells, such as with a protein they used to disable XPR1 in their experiments, could be an effective therapeutic strategy, the team added .
-
A new breakthrough in CAR-T: the number of cells required for therapeutic benefit is reduced by 5 times, thanks to this protein
Time of Update: 2022-10-16
On June 13, researchers from Washington University in St. Louis published an article in Nature Communications reporting that NeoImmuneTech's long-acting human IL-7 factor NT-17 combined with CAR-T therapy not only promoted CAR-T cell proliferation, but also increased Reduced cytotoxicity, reduced depletion and prolonged therapy durability .
-
Cancer: Why did you get cancer and not someone else?
Time of Update: 2022-10-16
The findings indicated that older age and smoking were the two most important risk factors associated with the 5-year relative and absolute risk of developing any cancer .
-
J Clin Oncol: Gefitinib vs gefitinib + carboplatin + pemetrexed in EGFR-mutant non-small cell lung cancer
Time of Update: 2022-10-16
This updated analysis showed that compared with gefitinib alone, the GCP regimen significantly improved progression-free survival in patients tested with an acceptable safety profile .
This updated analysis showed that compared with gefitinib alone, the GCP regimen significantly improved progression-free survival in patients tested with an acceptable safety profile .
-
Nature sub-journal: Identify ways to limit metastatic cancer growth!
Time of Update: 2022-10-16
html Cancer stem cells (CSCs) are key drivers behind the progression of malignant cancers with self-renewal, high metastases and resistance to therapy .
html Cancer stem cells (CSCs) are key drivers behind the progression of malignant cancers with self-renewal, high metastases and resistance to therapy .
-
Sci Adv: Wang Zefeng's team discovers a novel length-dependent splicing disorder widespread in cancer
Time of Update: 2022-10-16
The study first identified aberrantly spliced exons in cancer by analyzing large-scale cancer transcriptome data in the TCGA database, and found that the lengths of abnormally spliced exons in cancer tend to be shorter, and these short exons Exons are more likely to be skipped in cancer .
-
European Radiology: MRI Diffusion Signature Index for Noninvasive Evaluation of Histological Phenotype of Invasive Breast Cancer!
Time of Update: 2022-10-15
4 and the 85th percentile was 105The present study showed that quantitative diffusion MRI S-index values showed a high correlation with prognostic factors in invasive breast cancer, and the mean and 85th percentile S-index values could be used to predict HER2 and hormone receptor status .
